Comparison of Efficacy and Safety of 308 nm Excimer laser (targeted phototherapy) and Intralesional Triamcinolone (steroid) in treating Alopecia Areata (autoimmune disorder characterized by non-scarring hair loss)

Comparison of Efficacy and Safety of 308 nm Excimer laser and Intralesional Triamcinolone in treating Alopecia Areata - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094101

Enrollment

Registered

2025-09-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L638- Other alopecia areata

Interventions

Intervention1: 308 nm Excimer Laser: Patients will be given therapy twice weekly by Excimal Elite 308nm Excimer UV Light System, but not on consecutive days. The treatment will be started at 300 mJ/cm

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who give consent for the study 2. Age more than 7 years and less than 60 years 3. Patients with a diagnosis of patch type of alopecia areata 4. Patients presenting with less than 5 patches sizes 2cm to 5cm. 5. Subjects having patch for atleast 3 months with no evidence of hair regrowth 6. Patients who have never taken treatment or who have not taken treatment for atleast 8 weeks 7. Patients who are willing and capable of cooperating to the extent and degree required by the protocol.

Exclusion criteria

Exclusion criteria: 1. Patients who do not give consent. 2. Patients who received treatment within last 8 weeks. 3. Patients with alopecia totalis or alopecia universalis. 4. Patients with known photosensitivity like polymorphous light eruption, connective tissue diseases, porphyria, xeroderma pigmentosum. 5. Pregnant or breast feeding. 6. History of previous skin cancer. 7. Patient with history of existing skin disease affecting the scalp such as psoriasis.

Design outcomes

Primary

Measure	Time frame
Patients with more than 50% hair regrowth will be considered successful treatment. Response to treatment is graded according to therapeutic efficacy which is calculated using Severity of Alopecia tool score (SALT). Timepoint: 12 weeks	—

Secondary

Measure	Time frame
1. Treatment outcome rates Clinically a. Presence of positive or negative alopecia areata hair pull test. b. Presence or absence of short regrowing hair as evident clinically c. Percentage regrowth on 4 point scale Tricoscopic Findings a. Black dot b. Broken hair c. Tapering hair (exclamation mark hair) d. Coudability hair 2. Patient satisfaction Poor = 0-25 percentage Hair regrowth Fair = 26-50 percentage Hair regrowth Good = 51-75 percentage Hair regrowth Excellent = more than 75 percentage Hair regrowth Timepoint: 12 weeks	—

Measure

Time frame

1. Treatment outcome rates Clinically a. Presence of positive or negative alopecia areata hair pull test. b. Presence or absence of short regrowing hair as evident clinically c. Percentage regrowth on 4 point scale Tricoscopic Findings a. Black dot b. Broken hair c. Tapering hair (exclamation mark hair) d. Coudability hair 2. Patient satisfaction Poor = 0-25 percentage Hair regrowth Fair = 26-50 percentage Hair regrowth Good = 51-75 percentage Hair regrowth Excellent = more than 75 percentage Hair regrowth Timepoint: 12 weeks

—

Countries

India

Contacts

Public ContactDr Ajay Ovhal

Vilasrao Deshmukh Government Medical College, Latur

drajayovhal@gmail.com9422649911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026